|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
1992-11-27
|
|
pubmed:abstractText |
Chemical conversion of the potent anthelmintic natural products avermectin B1 (1) and avermectin B2 (3) to the corresponding 13-epi analogs (15 and 9) is described. The novel analogs retain the full potency of the natural products but are substantially safer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3873-8
|
|
pubmed:dateRevised |
2003-11-14
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Synthesis and biological activity of 13-epi-avermectins: potent anthelmintic agents with an increased margin of safety.
|
|
pubmed:affiliation |
Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.
|
|
pubmed:publicationType |
Journal Article
|
